Search in:

OncoTargets and Therapy Volume 14, 2021 - Issue

Submit an article Journal homepage

Open access

105

Views

CrossRef citations to date

Altmetric

Review

Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Hassaan Imtiaz1 Department of Internal Medicine, King Edward Medical University, Lahore, Punjab, Pakistan

Maimoona Khan2 Department of Medicine, Shifa College of Medicine, Islamabad, Pakistan

Hamid Ehsan3 Department of Hematology/Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA

https://orcid.org/0000-0002-4607-3171

Ahsan Wahab4 Hospital Medicine/Internal Medicine, Baptist Medical Center South, Montgomery, AL, USA

Abdul Rafae5 Department of Internal Medicine, McLaren Regional Medical Center, Flint, MI, USA

https://orcid.org/0000-0003-4113-3304

Ali Y Khan6 Department of Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, MI, USA

Abdur Jamil7 Department of Internal Medicine, Central Michigan University, Saginaw, MI, USA

Muhammad Khawar Sana8 Department of Internal Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USACorrespondence[email protected]

https://orcid.org/0000-0003-1952-8203

Abdullah Jamal1 Department of Internal Medicine, King Edward Medical University, Lahore, Punjab, Pakistan

Taimoor Jaffar Ali1 Department of Internal Medicine, King Edward Medical University, Lahore, Punjab, Pakistan

Iqraa Ansar2 Department of Medicine, Shifa College of Medicine, Islamabad, Pakistan

Muzammil M Khan9 Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA

Jack Khouri10 Hematology, Oncology, Stem Cell Transplantation, Multiple Myeloma Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, 44195, USA

Faiz Anwer10 Hematology, Oncology, Stem Cell Transplantation, Multiple Myeloma Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, 44195, USA

https://orcid.org/0000-0001-6914-7439

show all

Pages 4941-4960 | Published online: 01 Oct 2021

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Figures & data

Figure 1 PRISMA flowchart summary of the selection process.

Note: Copyright © 2009, Public Library of Science. Adapted with permission from Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.^Citation46

Table 1 Baseline Characteristics and Efficacy of Carfilzomib with Immunomodulators

Download CSV Display Table

Table 2 Baseline Characteristics and Efficacy of Carfilzomib with Alkylating Agents, Daratumumab, Quadruplet Regimens, and Other Proteasome Inhibitors

Download CSV Display Table

Table 3 Toxicity Profile of Carfilzomib-Based Regimens

Download CSV Display Table

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

Google Scholar

Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801–1809. doi:10.1182/blood-2012-04-422683

PubMed Web of Science ®Google Scholar

Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746–754. doi:10.1001/jamaoncol.2015.2010

PubMed Web of Science ®Google Scholar

Zimmerman T, Raje NS, Vij R, et al. Final results of a phase 2 trial of extended treatment (TX) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). Blood. 2016;128(22):675. doi:10.1182/blood.V128.22.675.675

Web of Science ®Google Scholar

Roussel M, Lauwers-Cances V, Robillard N, et al. Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the intergroupe francophone du myélome (IFM) krd phase II study. Blood. 2016;128(22):1142.

Web of Science ®Google Scholar

Jakubowiak AJ, Raje N, Vij R, et al. High rate of sustained minimal residual disease negativity predicts prolonged survival for the overall patient population in the phase 2 KRd plus autologous stem cell transplantation MMRC trial. Blood. 2017;130(Supplement 1):4533.

Google Scholar

Korde N, Mailankody S, Smith EL, et al. MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone. Blood. 2018;132:1983.

Google Scholar

Alsina M, Landgren CO, Raje N, et al. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM). Clin Lymphoma Myeloma Leuk. 2019;19(10):e52. doi:10.1016/j.clml.2019.09.079

Web of Science ®Google Scholar

Wester R, Van Der Holt B, Asselbergs E, et al. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the carthadex trial. Haematologica. 2019;104(11):2265–2273. doi:10.3324/haematol.2018.205476

PubMed Web of Science ®Google Scholar

Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, et al. Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. Blood Cancer J. 2020;10(3). doi:10.1038/s41408-020-0297-2

Web of Science ®Google Scholar

Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63–69. doi:10.1182/blood-2014-03-563759

PubMed Web of Science ®Google Scholar

Bensinger WI, Vescio R, Gasparetto C, et al. A multicenter phase 1b, open-label, dose-finding pilot study to evaluate the combination of carfilzomib and cyclophosphamide with dexamethasone (CCyD) prior to autologous stem cell transplant (ASCT) in patients with transplant eligible newly diagnosed multiple myeloma. Blood. 2014;124(21):4739–4739.

Web of Science ®Google Scholar

Moreau P, Kolb B, Attal M, et al. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood. 2015;125(20):3100–3104. doi:10.1182/blood-2015-02-626168

PubMed Web of Science ®Google Scholar

Boccia RV, Bessudo A, Agajanian R, et al. A multicenter, open-label, Phase 1b Study of carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients (CHAMPION-2). Clin Lymphoma Myeloma Leuk. 2017;17(7):433–437. doi:10.1016/j.clml.2017.05.009

PubMed Web of Science ®Google Scholar

Bringhen S, D’Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018;32(4):979–985. doi:10.1038/leu.2017.327

PubMed Web of Science ®Google Scholar

Chen Y, Gopalakrishnan S, Ooi M, et al. Carfilzomib, cyclophosphamide, and dexamethasone in transplant eligible newly diagnosed multiple myeloma: preliminary result of sghmm1 trial, high-risk cohort (NCT02217163). HemaSphere. 2018;2:589.

Google Scholar

Yong K, Popat R, Wilson W, et al. Efficacy and safety of carfilzomib at 56 mg/m2 with cyclophosphamide and dexamethasone (K56Cd) in newly diagnosed multiple myeloma patients followed by ASCT or K56Cd consolidation: initial results of the Phase 2 Cardamon Study. Blood. 2019;134(Supplement_1):861. doi:10.1182/blood-2019-127992

Google Scholar

Leleu X, Fouquet G, Richez V, et al. Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03): a phase I trial. Clin Cancer Res. 2019;25(14):4224–4230. doi:10.1158/1078-0432.CCR-18-3642

PubMed Web of Science ®Google Scholar

Chari A, Usmani SZ, Krishnan A, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRD) in patients with newly diagnosed multiple myeloma (mmy1001): updated results from an open-label, phase 1b study. Blood. 2017;130:3110.

Google Scholar

Costa LJ, Chhabra S, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based dara-KRd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134:860.

PubMed Web of Science ®Google Scholar

Landgren O, Sonneveld P, Jakubowiak A, et al. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019;33(9):1. doi:10.1038/s41375-019-0517-6

PubMed Web of Science ®Google Scholar

Weisel K, Asemissen AM, Schieferdecker A, et al. Isatuximab, carfilzomib, lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk multiple myeloma: results of the safety run-in cohort in the phase II, multicenter GMMG-CONCEPT trial. Clin Lymphoma Myeloma Leuk. 2019;19(10):e17. doi:10.1016/j.clml.2019.09.024

Web of Science ®Google Scholar

Mikhael JR, Reeder CB, Libby EN, et al. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol. 2015;169(2):219–227. doi:10.1111/bjh.13296

PubMed Web of Science ®Google Scholar

Pawlyn C, Davies F, Cairns D, et al. Quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide and dexamethasone) induction for newly diagnosed myeloma patients. Clin Lymphoma Myeloma Leuk. 2019;19(10):e2. doi:10.1016/j.clml.2019.09.003

Web of Science ®Google Scholar

Forsberg PA, Rossi AC, Boyer A, et al. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. Am J Hematol. 2019;94(5):539–545. doi:10.1002/ajh.25435

PubMed Web of Science ®Google Scholar

Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133(18):1953–1963. doi:10.1182/blood-2018-09-874396

PubMed Web of Science ®Google Scholar

Kumar S, Jacobus SJ, Cohen AD, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): results of ENDURANCE (E1A11) phase III trial. J Clin Oncol. 2020;38(18_suppl):LBA3–LBA. doi:10.1200/JCO.2020.38.18_suppl.LBA3

Web of Science ®Google Scholar

Bringhen S, Mina R, Petrucci M, et al. Incidence and risk factors of cardiovascular adverse events in a large population of newly-diagnosed, transplant ineligible myeloma patients treated with carfilzomib. In: Haematologica. Via Giuseppe Belli 4, 27100 Pavia, Italy: Ferrata Storti Foundation; 2017;102:510–511.

Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Table 1 Baseline Characteristics and Efficacy of Carfilzomib with Immunomodulators

Table 2 Baseline Characteristics and Efficacy of Carfilzomib with Alkylating Agents, Daratumumab, Quadruplet Regimens, and Other Proteasome Inhibitors

Table 3 Toxicity Profile of Carfilzomib-Based Regimens

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Figures & data

Table 1 Baseline Characteristics and Efficacy of Carfilzomib with Immunomodulators

Table 2 Baseline Characteristics and Efficacy of Carfilzomib with Alkylating Agents, Daratumumab, Quadruplet Regimens, and Other Proteasome Inhibitors

Table 3 Toxicity Profile of Carfilzomib-Based Regimens

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date